Literature DB >> 28888798

Impact of body mass index on treatment outcome of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Y Sun1, Z Xu1, H Lin1, X Lu1, Y Huang1, S Huang1, X Wang1, P Chi2.   

Abstract

AIM: To determine the effect of obesity, measured by body mass index (BMI), on tumor response and surgical outcome in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT) and radical surgery.
METHOD: LARC patients undergoing nCRT and radical surgery from 2008 to 2014 were included and divided into three groups: non-obese (BMI < 25.0 kg/m2), obese I (BMI 25.0-29.9 kg/m2), and obese II (BMI ≥ 30.0 kg/m2). Tumor response, surgical and oncological outcome were compared between groups. Multivariate analyses were performed to identify risk factors for local recurrence.
RESULTS: A total of 522 LARC patients were analyzed (407 non-obese, 93 obese I, 22 obese II). Post-operative complications did not differ between groups. Increased BMI was associated with poorer T downstaging and Rectal Cancer Regression Grade (P = 0.116, P = 0.036). With a mean follow-up of 57 months, the 5-year overall survival and distant metastasis rates did not differ between groups (P = 0.861, P = 0.116). The 5-year local recurrence rate in obese II patients was 14.6%, higher than that in non-obese and obese I groups (P = 0.015). Cox regression analysis demonstrated that BMI ≥30 kg/m2 (HR = 6.187, P = 0.010) was significantly associated with increased risk for local recurrence.
CONCLUSION: Obesity was associated with poorer T downstaging and Rectal Cancer Regression Grade, and thus poor local control in LARC following nCRT in Asian patients. More effective treatment strategies to improve treatment outcome for obese patients with LARC are warranted.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Body mass index; Chemoradiotherapy; Obesity; Outcome; Rectal cancer

Mesh:

Year:  2017        PMID: 28888798     DOI: 10.1016/j.ejso.2017.07.022

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  The effect of increased body mass index values on surgical outcomes after radical resection for low rectal cancer.

Authors:  Xubing Zhang; Qingbin Wu; Chaoyang Gu; Tao Hu; Liang Bi; Ziqiang Wang
Journal:  Surg Today       Date:  2019-02-18       Impact factor: 2.549

2.  Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma.

Authors:  Sabine Semrau; Susanne Merkel; Valerie K B Kohl; Klaus Weber; Maximilian Brunner; Carol I Geppert; Rainer Fietkau; Robert Grützmann
Journal:  Int J Colorectal Dis       Date:  2022-05-11       Impact factor: 2.796

3.  Obesity may not be related to pathologic response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy.

Authors:  Quoc Riccardo Bao; Filippo Crimì; Giovanni Valotto; Valentina Chiminazzo; Francesca Bergamo; Alessandra Anna Prete; Sara Galuppo; Badr El Khouzai; Emilio Quaia; Salvatore Pucciarelli; Emanuele Damiano Luca Urso
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

4.  Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A retrospective cohort study.

Authors:  Bingjie Guan; Xinmin Huang; Huang Xia; Guoxian Guan; Benhua Xu
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

5.  High body mass index is associated with an increased overall survival in rectal cancer.

Authors:  Karolina Juszczyk; Sharlyn Kang; Soni Putnis; Robert Winn; James Chen; Morteza Aghmesheh; Glaucia Fylyk; Daniel Brungs
Journal:  J Gastrointest Oncol       Date:  2020-08

6.  Overweight but not obesity is associated with decreased survival in rectal cancer.

Authors:  Leonardo S Lino-Silva; Eduardo Aguilar-Cruz; Rosa A Salcedo-Hernández; César Zepeda-Najar
Journal:  Contemp Oncol (Pozn)       Date:  2018-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.